Telangana Unveils 1 Bio Bioprocess Hub at Genome Valley to Accelerate Biologics Development

Telangana has launched 1 Bio at Genome Valley, a 150,000 sq ft bioprocess hub to support end-to-end process development and enable organizations to scale bioprocesses without heavy upfront costs.

Telangana has launched 1 Bio, a dedicated bioprocess design and scale-up hub at Genome Valley, marking a significant expansion of India’s biologics innovation infrastructure.

The facility is positioned as the country’s first single-use bioprocess design center, supporting the development of biologics and next-generation therapeutics through shared, pilot-ready infrastructure.

The hub, spread across 2 acres and comprising 150,000 sq ft of R&D and analytical laboratories, offers plug-and-play innovation suites, bioprocess training labs, downstream processing systems and validation units.

It is structured to provide end-to-end process development and pilot-scale support so that organizations can test, optimize and scale bioprocesses without large upfront capital expenditure on their own facilities.

1 Bio has been established through a collaboration led by the Government of Telangana, supported by Telangana Lifesciences, Telangana State Industrial Infrastructure Corporation (TSIIC), the Department of Biotechnology and Thermo Fisher Scientific.

The state invested ₹150 crore towards the physical infrastructure, while Thermo Fisher contributed ₹90 crore to set up the bioprocess design center and a co-located customer experience facility.

Inaugurating the hub, Duddilla Sridhar Babu, Minister for Industries and IT, Government of Telangana, said, “1 Bio is one of India’s most important steps toward democratizing access to biologics scale-up and accelerating the journey from discovery to clinical readiness. With this facility, innovations developed in India or anywhere in the world can progress to pilot and clinical stages in Hyderabad faster, more predictably and at lower cost.”

He added that the state commits an additional ₹200 crore in new and upgraded infrastructure to support Genome Valley’s next phase of growth. The centre is designed to support the development of monoclonal antibodies, recombinant proteins, vaccines and other biomolecules that require specialised bioprocess validation.

Sanjay Kumar, Special Chief Secretary, IT and Industries, Government of Telangana, stated that the state accounts for “around 40 per cent of India’s pharmaceutical production and nearly one third of global vaccine manufacturing,” underlining the strategic importance of expanding upstream biologics capabilities through infrastructure such as 1 Bio.

Shakthi M Nagappan, CEO, Telangana Life Sciences Foundation, explained that the launch of 1 Bio addresses “one of the most critical missing links” in India’s biologics ecosystem by offering specialised infrastructure for process validation, training and early-stage production.

Officials highlighted that 1 Bio works in alignment with existing Genome Valley platforms to expand the cluster’s role beyond manufacturing into a more integrated innovation-to-scale ecosystem for biologics and life sciences.

Stay tuned for more such updates on Digital Health News